-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Industry News] The acceptance of IPOs on the Science and Technology Innovation Board is ushering in a "rush for examinations"
.
Since the second half of 2022, the number of companies that have accepted applications on the Science and Technology Innovation Board has surged, of which 26 companies have been accepted for listing applications in just one week in June (June 19 to 26)
.
It is worth noting that another medical company will be listed today
.
On August 18, United Imaging Medical announced that the company's shares will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on August 22, 2022
.
The issuance price of United Imaging Medical is 109.
88 yuan per share.
After the completion of this issuance, the total number of shares is 824,157,988 shares, and the price-earnings ratio is 77.
69 times
.
After the successful issuance, the market value of United Imaging Medical is expected to reach 90.
5 billion yuan
.
United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions.
The product line covers MR products, CT products, XR products, MI products and RT products as well as life scientific instruments,
etc.
At the end of last year, United Imaging Medical's application for listing on the Science and Technology Innovation Board was accepted, with a financing amount of 12.
48 billion yuan and a proposed issuance value of 104.
1 billion yuan
.
It is understood that United Imaging Medical plans to use nearly half of the funds raised in the IPO for "next-generation product research and development projects", which is greater than the company's total R&D expenditures in the first four years
.
In fact, in addition to United Imaging Medical, a number of pharmaceutical companies have recently passed their registration applications for listing on the Science and Technology Innovation Board, including Mengke Pharmaceuticals, Xuantai Pharmaceuticals, etc.
, mainly involving biopharmaceuticals, medical devices and other industries
.
It is worth noting that at present, not only pharmaceutical companies on the Science and Technology Innovation Board are actively listed, but in early July, A-share IPO acceptance companies ushered in a big explosion, with a total of 275 new acceptance companies
.
Among them, there are 13 pharmaceutical manufacturing enterprises.
Specifically, 4 are accepted by the ChiNext, 2 are accepted by the Shenzhen Main Board, 2 are accepted by the Beijing Stock Exchange, and 1 are accepted by the Shanghai Main Board
.
Recently, these sectors have also ushered in another batch of drug companies applying for listing
.
As reported on August 18, Guangzhou Yinming Biomedical Technology Co.
, Ltd.
(hereinafter referred to as "Yinming Bio") has also formally submitted a prospectus to the Hong Kong Stock Exchange on August 17, and the company plans to be listed on the main board
.
According to the data, Yinming Bio is an innovation-driven biopharmaceutical company dedicated to the independent discovery and development of potential First-in-Class, and is committed to solving the major unmet clinical needs in many medical fields around the world
.
The company is mainly engaged in medical research and experimental development (except human stem cells, gene diagnosis and treatment technology); biomedical technology research (except human stem cells, gene diagnosis and treatment technology); drug research and development (except human stem cells, gene diagnosis and treatment technology); Data processing and storage services; data processing and storage product design,
etc.
Due to the rich product line of MingBio, it currently has at least seven self-developed drugs under development, covering four major fields: ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs and pet immune drugs
.
It is worth noting that industry analysts believe that this year, new pharmaceutical stocks have been under pressure
.
According to incomplete statistics, among the 137 new stocks listed since 2022, 73 new stocks have broken
.
Therefore, it remains to be seen how the upcoming new shares will perform
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
.
Since the second half of 2022, the number of companies that have accepted applications on the Science and Technology Innovation Board has surged, of which 26 companies have been accepted for listing applications in just one week in June (June 19 to 26)
.
It is worth noting that another medical company will be listed today
.
On August 18, United Imaging Medical announced that the company's shares will be listed on the Science and Technology Innovation Board of the Shanghai Stock Exchange on August 22, 2022
.
The issuance price of United Imaging Medical is 109.
88 yuan per share.
After the completion of this issuance, the total number of shares is 824,157,988 shares, and the price-earnings ratio is 77.
69 times
.
After the successful issuance, the market value of United Imaging Medical is expected to reach 90.
5 billion yuan
.
United Imaging Medical is committed to providing global customers with high-performance medical imaging equipment, radiotherapy products, life science instruments and medical digital and intelligent solutions.
The product line covers MR products, CT products, XR products, MI products and RT products as well as life scientific instruments,
etc.
At the end of last year, United Imaging Medical's application for listing on the Science and Technology Innovation Board was accepted, with a financing amount of 12.
48 billion yuan and a proposed issuance value of 104.
1 billion yuan
.
It is understood that United Imaging Medical plans to use nearly half of the funds raised in the IPO for "next-generation product research and development projects", which is greater than the company's total R&D expenditures in the first four years
.
In fact, in addition to United Imaging Medical, a number of pharmaceutical companies have recently passed their registration applications for listing on the Science and Technology Innovation Board, including Mengke Pharmaceuticals, Xuantai Pharmaceuticals, etc.
, mainly involving biopharmaceuticals, medical devices and other industries
.
It is worth noting that at present, not only pharmaceutical companies on the Science and Technology Innovation Board are actively listed, but in early July, A-share IPO acceptance companies ushered in a big explosion, with a total of 275 new acceptance companies
.
Among them, there are 13 pharmaceutical manufacturing enterprises.
Specifically, 4 are accepted by the ChiNext, 2 are accepted by the Shenzhen Main Board, 2 are accepted by the Beijing Stock Exchange, and 1 are accepted by the Shanghai Main Board
.
Recently, these sectors have also ushered in another batch of drug companies applying for listing
.
As reported on August 18, Guangzhou Yinming Biomedical Technology Co.
, Ltd.
(hereinafter referred to as "Yinming Bio") has also formally submitted a prospectus to the Hong Kong Stock Exchange on August 17, and the company plans to be listed on the main board
.
According to the data, Yinming Bio is an innovation-driven biopharmaceutical company dedicated to the independent discovery and development of potential First-in-Class, and is committed to solving the major unmet clinical needs in many medical fields around the world
.
The company is mainly engaged in medical research and experimental development (except human stem cells, gene diagnosis and treatment technology); biomedical technology research (except human stem cells, gene diagnosis and treatment technology); drug research and development (except human stem cells, gene diagnosis and treatment technology); Data processing and storage services; data processing and storage product design,
etc.
Due to the rich product line of MingBio, it currently has at least seven self-developed drugs under development, covering four major fields: ophthalmic drugs, recombinant protein botulinum toxin, tumor immune drugs and pet immune drugs
.
It is worth noting that industry analysts believe that this year, new pharmaceutical stocks have been under pressure
.
According to incomplete statistics, among the 137 new stocks listed since 2022, 73 new stocks have broken
.
Therefore, it remains to be seen how the upcoming new shares will perform
.
Disclaimer: Under no circumstances does the information or opinions expressed in this article constitute investment advice to anyone
.
